Skip to main content
OpenTrials
Completed

NCT Number: NCT04451928

Prediction of Preterm Delivery by Serum Ischemia Modified Albumin, Biglycan and Decorin Levels in Women With Threatened Preterm Labour

In this study, the levels of ischemia modified albumin, biglycan and decorin in the serums of pregnant women hospitalized for preterm labor will be examined. Their serum levels will be compared between women having preterm and term delivery. Their accuracy will be asessed in predicting preterm birth.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–42 year

Sex eligibility

Female

Study type

Observational

Primary location

Kütahya Medical Sciences University

Kütahya, 43000, Turkey (Türkiye)

About this study

The study will include 90 singleton pregnant women between the ages of 18 and 42 and gestational ages of 24 and 37 weeks.

Inclusion criteria

  • Singleton pregnancy
  • Gestational age between 24 and 37 weeks
  • Cervical dilatation less than 3 cm and cervical effacement less than 80%
  • Uterine contraction ≥3 times at 30 minutes
  • Intact amniotic membrane

Excusion criteria:

  • Multiple pregnancy
  • Preterm premature rupture of membranes
  • Abnormal placentation (such as placenta previa)
  • Uterin anomaly
  • Maternal heart disease
  • Inflammatory or infectious disease
  • Preeclampsia
  • Fetal growth restriction
  • Congenital fetal anomaly
  • Polyhydramnios
  • Acute chorioamnionitis
  • Medically induced preterm delivery

Patients who are hospitalized due to preterm labor will primarily receive bed rest and hydration. If cervical changes persist or if contractions continue after 2 hours after intravenous hydration, tocolytic treatment will be started. Calcium channel blockers will be used as tocolytic drug. Maternal corticosteroid (12 mg intramuscular betamethasone within 24 hours) will be given to accelerate fetal lung development. After 48 hours after steroid administration, tocolysis will be stopped. Demographic datas of the patients will be recorded. Patients will be followed until delivery. The gestational week will be determined according to the last menstrual date and will be confirmed by early ultrasonographic measurements. The gestational week at birth and the time between admission to the hospital and birth will be recorded. Delivery time will be divided into groups within 24 hours, 48 hours, 7 days, 14 days, and ≤37 weeks after admission. Mode of delivery, baby's birth weight, APGAR score will be recorded.

Venous blood samples will be taken from patients before medication. Serum samples will be stored in the cooler set to -80 °C until analysis. Levels of ischemia-modified albumin, biglycan and decorin levels will be examined by enzyme-linked immunosorbent assay (ELISA) method.

Statistical analysis:

After the assessment of the data, the variables between two groups will be compared by Mann Whitney U test, Student T test, Fisher Exact Test, Chi-Square Analysis. Regression model will be conducted in order to estimate the probability of the preterm birth. A value of p < 0.05 will be considered statistically significant.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Singleton pregnancy
  • Gestational age is between 24-37 weeks
  • Cervical dilatation less than 3 cm and cervical effacement less than 80%
  • Uterine contraction ≥3 times at 30 minutes
  • Intact amniotic membrane

Exclusion criteria

  • Multiple pregnancy
  • Preterm premature rupture of membranes
  • Abnormal placentation (such as placenta previa)
  • Uterine anomaly
  • Maternal heart disease
  • Inflammatory or infectious disease
  • Preeclampsia
  • Fetal growth restriction
  • Congenital fetal anomaly
  • Polyhydramnios
  • Acute chorioamnionitis
  • Medically induced preterm delivery

Treatment and study plan

Serum sample analysis

Diagnostic Test

Analysis of the levels of ischemia-modified albumin, biglycan and decorin levels

Primary outcomes

  1. Gestational age at birth

    Time frame: December 2019 - January 2021

    Preterm: <37 gestational week Term: ≥37 gestational week

Secondary outcomes

  1. Hospital admission and delivery interval

    Time frame: December 2019 - January 2021

    Delivery time will be divided into groups within; 48 hours, 7 days, 14 days,

    • 35 weeks and
    • 37 weeks after hospital admission.
  2. Mode of delivery

    Time frame: December 2019 - January 2021

    Vaginal delivery Cesarean delivery

  3. APGAR score

    Time frame: December 2019 - January 2021

    Apgar stands for "Appearance, Pulse, Grimace, Activity, and Respiration." of newborn at 1 and 5 minutes after delivery.

Sponsors and collaborators

Lead sponsor

Ismail Biyik

Other

Registry information

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Jun 30, 2020
Registry last updated
Mar 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.